Literature DB >> 23881510

Allergen immunotherapy extract treatment set preparation: making a safer and higher quality product for patients.

Michael R Nelson1, Maureen M Petersen, Wayne O Wolverton, Cecilia P Mikita.   

Abstract

The best possible allergen immunotherapy clinical outcomes require the provision of high quality and safe allergen immunotherapy extract preparations. Evolving national guidelines and regulatory bodies have devoted special attention to the safe compounding of sterile products, including allergen extracts. It is incumbent upon allergists preparing extract treatment sets for patients to be familiar with and adopt training, procedures and safety measures that lead to standardized high quality products. Preparers and supervisors must maintain ongoing competency in aseptic technique and prescribing principles, such as probable effective dose ranges, allergen cross-reactivity, and separation of high protease-containing extracts from susceptible extracts. Accordingly, knowledge and application of vial labeling, diluent selection, standard operating procedures, mixing log documentation, and mixing condition principles are a necessity. Although there have been no instances of infectious complications from allergen immunotherapy in a century of clinical practice, continued vigilance in the use of measures that ensure extract sterility is paramount. A review of allergen immunotherapy preparation recommendations and best practices based on published national guidelines is presented. Further study of preparation measures and prescribing principles will continue to advance the practice of allergen immunotherapy and offer opportunities for refinement of current recommendations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881510     DOI: 10.1007/s11882-013-0362-z

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  20 in total

1.  Monitoring bacteriostasis in allergen extract mixing: 10 years of culture data.

Authors:  Adrian G Letz; Michael S Tankersley; John P Dice; Ronald W England
Journal:  J Allergy Clin Immunol       Date:  2009-02-28       Impact factor: 10.793

Review 2.  Preparing and mixing allergen vaccines for subcutaneous immunotherapy.

Authors:  Harold S Nelson
Journal:  Clin Allergy Immunol       Date:  2008

3.  Effect of dilution, temperature, and preservatives on the long-term stability of standardized inhalant allergen extracts.

Authors:  N R Niemeijer; H F Kauffman; W van Hove; A E Dubois; J G de Monchy
Journal:  Ann Allergy Asthma Immunol       Date:  1996-06       Impact factor: 6.347

4.  Pain and dermal reaction caused by injected glycerin in immunotherapy solutions.

Authors:  T E Van Metre; G L Rosenberg; S K Vaswani; S R Ziegler; N F Adkinson
Journal:  J Allergy Clin Immunol       Date:  1996-05       Impact factor: 10.793

5.  Cross allergenicity among grasses determined by tissue threshold changes.

Authors:  D C Leavengood; R L Renard; B G Martin; H S Nelson
Journal:  J Allergy Clin Immunol       Date:  1985-12       Impact factor: 10.793

Review 6.  Allergen immunotherapy practice in the United States: guidelines, measures, and outcomes.

Authors:  Linda Cox; Robert E Esch; Mark Corbett; Cheryl Hankin; Michael Nelson; Greg Plunkett
Journal:  Ann Allergy Asthma Immunol       Date:  2011-07-31       Impact factor: 6.347

7.  Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts.

Authors:  Thomas J Grier; Dawn M LeFevre; Elizabeth A Duncan; Robert E Esch
Journal:  Ann Allergy Asthma Immunol       Date:  2007-08       Impact factor: 6.347

8.  Extensive IgE cross-reactivity towards the Pooideae grasses substantiated for a large number of grass-pollen-sensitized subjects.

Authors:  Niels Johansen; Richard W Weber; Henrik Ipsen; Domingo Barber; Louise Broge; Charlotte Hejl
Journal:  Int Arch Allergy Immunol       Date:  2009-07-01       Impact factor: 2.749

Review 9.  Stability of allergen extracts used in skin testing and immunotherapy.

Authors:  Greg Plunkett
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2008-06       Impact factor: 2.064

10.  Allergen vial mixing and immunotherapy: Risks of infections and vial contamination.

Authors:  P Chase Lay; Richard Bass; Sandra Y Lin
Journal:  Otolaryngol Head Neck Surg       Date:  2007-08       Impact factor: 3.497

View more
  3 in total

1.  Allergen Valency, Dose, and FcεRI Occupancy Set Thresholds for Secretory Responses to Pen a 1 and Motivate Design of Hypoallergens.

Authors:  Avanika Mahajan; Lama A Youssef; Cédric Cleyrat; Rachel Grattan; Shayna R Lucero; Christopher P Mattison; M Frank Erasmus; Bruna Jacobson; Lydia Tapia; William S Hlavacek; Mark Schuyler; Bridget S Wilson
Journal:  J Immunol       Date:  2016-12-30       Impact factor: 5.422

2.  Cardiac urticaria caused by eucleid allergen.

Authors:  Xiaodong Zhan; Chaopin Li; Qianwen Wu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 3.  Towards definitive management of allergic rhinitis: best use of new and established therapies.

Authors:  Lubnaa Hossenbaccus; Sophia Linton; Sarah Garvey; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2020-05-27       Impact factor: 3.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.